Acticor Biotech: Half-year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

Regulatory News:

ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.

Under the liquidity contract entered into between ACTICOR BIOTECH and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th, 2024:

- 245,176 shares - € 252,168.60 - Number of executions on buy side on semester: 990 - Number of executions on sell side on semester: 956 - Traded volume on buy side on semester: 504,480 shares for € 524,812.30 - Traded volume on sell side on semester: 324,426 shares for € 473,133.44

As a reminder:

• the following resources appeared on the last half year statement on 31 December 2023 on the liquidity account:

- 65,122 shares - € 299,098.61 - Number of executions on buy side on semester: 340 - Number of executions on sell side on semester: 227 - Traded volume on buy side on semester: 39,590 shares for € 173,764.12 - Traded volume on sell side on semester: 17,891 shares for € 85,132.33

• the following resources appeared on the liquidity account when the activity started:

- 0 shares - € 600,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

About ACTICOR BIOTECH

Acticor Biotech is a clinical-stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, particularly ischemic stroke.

The positive results of the phase 1b/2a study, ACTIMIS, published in January 2024 in the Lancet Neurology (link to publication) confirmed the safety profile of glenzocimab and showed a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group of stroke patients. A post-hoc analysis of brain imaging at 0 and 24 hours using artificial intelligence confirmed these results, showing a reduction in the number and volume of intracerebral lesions in patients treated with glenzocimab.

On April 25, 2024, the company announced the initial results of the international phase 2/3 ACTISAVE study in the treatment of acute ischemic stroke, which showed no efficacy of glenzocimab on the primary endpoint, the proportion of patients with severe disability or death (mRS 4-6) 90 days after stroke, nor on the secondary endpoint, the proportion of patients returning to life without disability (mRS 0-2).

On May 15, 2024, Prof. Martin KÃhrmann (Principal Investigator of ACTISAVE) presented the main results of the study at the opening session of the European Stroke Organization Conference (ESOC), confirming the neutrality of the study on the primary and secondary endpoints, and showing trends in return to normal life (mRS 0-1), notably in sub-populations of patients with complete recanalization after mechanical thrombectomy.

Glenzocimab is being evaluated in 2 other clinical trials initiated by academic teams:

• GREEN: a phase 2/3 study in the treatment of stroke in thrombectomized patients, with a futility analysis after inclusion of the first 78 patients (30% of patients) expected in Q4 2024;
• LIBERATE: a Phase 2b LIBERATE trial in the treatment of myocardial infarction, with final results expected in Q4 2025.

Acticor Biotech is supported by a panel of European and international investors (Mediolanum farmaceutici, Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Anaxago, and the Armesa Foundation) and has been listed on Euronext Growth Paris since November 2021 (ISIN: FR0014005OJ5 - ALACT).

For more information, visit: www.acticor-biotech.com

 

Buy Side

 

Sell Side

 

Number of executions

Number of shares

Traded volume in EUR

 

Number of executions

Number of shares

Traded volume in EUR

Total

990

504,480

524,812.30

 

956

324,426

473,133.44

02/01/2024

1

250

725.00

 

2

250

737.50

05/01/2024

3

251

740.45

 

1

1

2.97

08/01/2024

-

-

-

 

8

750

2,257.50

09/01/2024

-

-

-

 

5

675

2,112.75

10/01/2024

1

100

306.00

 

3

25

79.00

11/01/2024

6

901

2,703.00

 

3

251

778.10

12/01/2024

6

1,223

3,510.01

 

4

501

1,477.95

15/01/2024

5

500

1,435.00

 

4

159

457.92

16/01/2024

2

250

710.00

 

4

108

312.12

17/01/2024

5

500

1,420.00

 

1

83

237.38

18/01/2024

1

1

2.84

 

3

501

1,437.87

19/01/2024

3

188

537.68

 

4

250

725.00

22/01/2024

-

-

-

 

4

750

2,227.50

23/01/2024

-

-

-

 

36

6,500

28,535.00

24/01/2024

-

-

-

 

38

5,726

30,004.24

25/01/2024

17

2,000

8,960.00

 

8

994

4,622.10

26/01/2024

6

750

3,232.50

 

3

402

1,776.84

29/01/2024

8

750

3,285.00

 

7

604

2,742.16

30/01/2024

4

463

2,046.46

 

3

750

3,367.50

31/01/2024

6

1,037

4,490.21

 

2

500

2,190.00

01/02/2024

12

1,000

4,260.00

 

-

-

-

02/02/2024

6

750

3,157.50

 

2

250

1,090.00

05/02/2024

7

500

2,100.00

 

5

501

2,134.26

06/02/2024

7

660

2,831.40

 

4

500

2,200.00

07/02/2024

5

395

1,666.90

 

3

501

2,169.33

08/02/2024

10

1,274

5,287.10

 

9

815

3,423.00

09/02/2024

4

267

1,148.10

 

5

686

3,018.40

12/02/2024

3

503

2,213.20

 

2

497

2,211.65

13/02/2024

4

731

3,135.99

 

1

1

4.43

14/02/2024

5

850

3,638.00

 

3

376

1,650.64

15/02/2024

2

399

1,687.77

 

-

-

-

16/02/2024

1

250

1,075.00

 

13

2,123

9,426.12

19/02/2024

3

250

1,100.00

 

1

250

1,125.00

20/02/2024

6

950

4,284.50

 

6

1,250

5,700.00

21/02/2024

-

-

-

 

22

1,877

8,859.44

22/02/2024

-

-

-

 

14

1,623

8,098.77

23/02/2024

-

-

-

 

12

1,250

6,287.50

26/02/2024

8

1,250

6,075.00

 

2

456

2,252.64

27/02/2024

7

751

3,717.45

 

17

2,244

11,264.88

 28/02/2024

3

500

2,510.00

 

25

2,001

10,145.07

29/02/2024

7

1,001

4,984.98

 

15

999

5,094.90

01/03/2024

4

1,000

5,020.00

 

21

3,274

16,992.06

04/03/2024

27

1,748

8,477.80

 

7

782

3,831.80

05/03/2024

1

5

24.70

 

15

2,718

13,617.18

06/03/2024

-

-

-

 

16

1,750

8,925.00

07/03/2024

8

831

4,188.24

 

3

144

740.16

08/03/2024

27

4,998

22,840.86

 

9

988

4,544.80

11/03/2024

10

1,940

8,749.40

 

8

689

3,128.06

12/03/2024

5

651

2,942.52

 

4

498

2,280.84

13/03/2024

6

950

4,294.00

 

5

514

2,343.84

14/03/2024

13

2,576

11,257.12

 

8

702

3,130.92

15/03/2024

28

4,721

15,248.83

 

-

-

-

18/03/2024

11

2,500

8,250.00

 

-

-

-

19/03/2024

15

3,100

9,486.00

 

-

-

-

20/03/2024

11

2,750

7,975.00

 

-

-

-

21/03/2024

8

1,272

3,739.68

 

-

-

-

22/03/2024

10

1,978

5,657.08

 

-

-

-

25/03/2024

7

410

1,271.00

 

-

-

-

26/03/2024

3

97

300.70

 

-

-

-

27/03/2024

3

252

806.40

 

-

-

-

28/03/2024

2

498

1,628.46

 

-

-

-

02/04/2024

2

500

1,635.00

 

-

-

-

03/04/2024

2

500

1,610.00

 

-

-

-

04/04/2024

1

36

118.80

 

-

-

-

05/04/2024

1

250

835.00

 

-

-

-

08/04/2024

2

250

850.00

 

-

-

-

09/04/2024

1

250

850.00

 

-

-

-

10/04/2024

3

110

374.00

 

-

-

-

11/04/2024

2

390

1,337.70

 

-

-

-

12/04/2024

4

500

1,800.00

 

-

-

-

15/04/2024

3

456

1,673.52

 

-

-

-

16/04/2024

7

664

2,529.84

 

2

500

1,965.00

17/04/2024

3

250

975.00

 

3

699

2,775.03

18/04/2024

1

46

185.84

 

4

301

1,219.05

19/04/2024

-

-

-

 

9

1,318

5,496.06

22/04/2024

21

6,943

26,730.55

 

17

2,250

8,775.00

23/04/2024

3

199

754.21

 

6

750

2,887.50

24/04/2024

9

2,048

7,864.32

 

11

2,250

9,022.50

25/04/2024

17

45,000

13,950.00

 

-

-

-

26/04/2024

53

110,000

42,900.00

 

-

-

-

29/04/2024

14

6,518

2,542.02

 

7

5,000

2,100.00

30/04/2024

23

17,982

6,653.34

 

10

4,000

1,560.00

02/05/2024

21

16,355

6,214.90

 

7

6,000

2,520.00

03/05/2024

1

1,000

390.00

 

1

1,000

400.00

06/05/2024

1

1,000

400.00

 

4

4,000

1,680.00

07/05/2024

5

4,000

2,000.00

 

48

32,792

17,051.84

08/05/2024

5

4,000

2,840.00

 

74

44,208

32,713.92

09/05/2024

59

24,740

20,039.40

 

31

14,412

12,394.32

10/05/2024

16

11,900

7,735.00

 

34

21,180

16,308.60

13/05/2024

22

11,700

8,892.00

 

14

8,000

6,320.00

14/05/2024

8

6,000

4,620.00

 

25

13,000

10,530.00

15/05/2024

-

-

-

 

47

27,593

28,420.79

16/05/2024

30

16,406

15,913.82

 

18

11,000

11,550.00

17/05/2024

7

7,000

6,650.00

 

5

1,227

1,202.46

20/05/2024

19

10,094

9,387.42

 

9

3,984

3,784.80

21/05/2024

17

9,700

8,827.00

 

9

4,625

4,301.25

22/05/2024

9

5,000

4,550.00

 

7

2,274

2,092.08

23/05/2024

6

5,000

4,350.00

 

1

25

22.75

24/05/2024

11

4,004

3,323.32

 

-

-

-

27/05/2024

12

5,996

4,916.72

 

-

-

-

28/05/2024

10

6,000

4,680.00

 

-

-

-

29/05/2024

10

3,428

2,639.56

 

4

3,000

2,370.00

30/05/2024

21

13,952

10,045.44

 

-

-

-

31/05/2024

8

4,620

3,095.40

 

-

-

-

03/06/2024

-

-

-

 

10

4,000

3,240.00

04/06/2024

-

-

-

 

41

24,165

23,681.70

05/06/2024

-

-

-

 

7

4,915

5,603.10

06/06/2024

11

8,000

7,520.00

 

2

165

181.50

07/06/2024

2

1,000

920.00

 

-

-

-

10/06/2024

13

10,000

8,600.00

 

6

1,000

880.00

11/06/2024

9

4,500

3,780.00

 

-

-

-

12/06/2024

7

4,001

3,280.82

 

4

3,001

2,520.84

13/06/2024

18

7,866

6,371.46

 

1

424

360.40

14/06/2024

27

22,134

15,493.80

 

31

4,587

3,256.77

17/06/2024

13

9,969

6,778.92

 

13

5,543

4,046.39

18/06/2024

-

-

-

 

16

4,300

3,010.00

19/06/2024

7

1,774

1,224.06

 

-

-

-

20/06/2024

5

1,226

858.20

 

8

4,800

3,552.00

24/06/2024

2

500

380.00

 

2

770

592.90

25/06/2024

12

5,000

3,700.00

 

5

398

302.48

26/06/2024

11

4,019

2,893.68

 

2

930

669.60

27/06/2024

3

1,001

710.71

 

1

1

0.72

28/06/2024

7

4,981

3,486.70

 

-

-

-

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240718435279/en/

ACTICOR BIOTECH Gilles AVENARD, MD CEO and Founder [e-mail] T. : [phone]

Sophie BINAY, PhD General Manager and CSO [e-mail] T. : [phone]

NewCap Mathilde BOHIN Investor Relations [e-mail] T. : [phone]

NewCap Arthur ROUILLÉ Media Relations [e-mail] T. : [phone]